Rallybio(RLYB) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Corporate Updates • In the third quarter of 2025, Rallybio generated a total of $20 million pursuant to its agreement with Recursion Pharmaceuticals for the sale of its interest in REV102, an investigational ENPP1 inhibitor in development for the treatment of hypophosphatasia (HPP). The total included $7.5 million from an upfront payment and $12.5 million related to the initiation of additional preclinical studies. RLYB116 Program Rallybio Reports Third Quarter 2025 Financial Results and Provid ...